FDA Approval: Blinatumomab for Patients With B-Cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission With Minimal Residual Disease
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2337
Full Text
Open PDFAbstract
Available in full text
Date
January 15, 2019
Authors
Publisher
American Association for Cancer Research (AACR)